Fig. 2: Inhibition of LRRK2 kinase activity increases GCase activity in DA neurons from PD patients.

Examination of lysosomal GCase activity in LRRK2 G2019S DA neurons treated with the LRRK2 kinase inhibitor, MLi-2 (600 nM) a. Comparison of GCase activity in LRRK2 G2019S b and R1441C c DA neurons relative to isogenic controls and neurons treated with MLi-2 or a direct GCase modulating compound, 6166 (3 µM). GCase activity measured in DA neurons from two independent healthy controls treated with MLi-2 d. Comparison of GCase activity in GBA1 E326K e or N370S f DA neurons relative to isogenic controls and neurons treated with MLi-2 or 6166. The data are presented as the mean ± SEM, n = 3; *p < 0.05, **p < 0.01, ***p < 0.001 relative to untreated, one-way ANOVA followed by Tukey’s multiple comparison post hoc test. Source data are provided as a Source Data file.